All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Formulary
Back
Contact us about this page
Chapter 6: Endocrine
Toggle Parent Pages
Print this page
Type 2 Diabetes Mellitus Treatment Guidance
Management of thyroid disorders
Guidance on the management of menopause
Management of osteoporosis
Prevention of glucocorticoid induced osteoporosis
Gender dysphoria and transgender prescribing
6.1 Drugs used in diabetes
6.2 Thyroid and antithyroid drugs
6.3 Corticosteroids
6.4 Sex hormones
6.5 Hypothalamic and pituitary hormones and anti-oestrogens
6.6 Drugs affecting bone metabolism
6.7 Other endocrine drugs
Page last updated:
6 May 2021
Contact us about this page
6.7.5 Metreleptin
First Line
Second Line
Specialist
Hospital Only
Metreleptin
- Powder for solution for injection vials 3mg, 5.8mg, 11.3mg
Notes
- NICE HST14: Metreleptin for treating lipodystrophy (February 2021):
- Metreleptin (Myalepta) is recommended, within its marketing authorisation, as an option for treating the complications of leptin deficiency in lipodystrophy for people who are 2 years and over and have generalised lipodystrophy
- Metreleptin (Myalepta) is recommended as an option for treating the complications of leptin deficiency in lipodystrophy for people who are 12 years and over, have partial lipodystrophy, and do not have adequate metabolic control despite having standard treatments. It is only recommended if they have an HbA1c level above 7.5%, or fasting triglycerides above 5.0mmol/litre, or both
